Personalized immune vaccine for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a new personalized vaccine made from your own tumor cells. It's for people with advanced melanoma that hasn't responded to standard immunotherapy. The goal is to see if this vaccine can help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have melanoma that cannot be removed by surgery or has spread, and standard anti-PD-1 therapy (like Keytruda or Opdivo) has stopped working.
- You have a tumor that can be surgically removed or biopsied (at least the size of about 5 pencil-eraser tips) to make the vaccine, plus at least one other measurable tumor.
- You can pause your current anti-PD-1 treatment for about 6 weeks.
- You are generally healthy enough for daily activities (ECOG score 0 or 1), and your kidney, liver, and blood cell counts are within certain limits.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a personalized cell therapy using your own immune cells (tumor-infiltrating lymphocytes, or TILs) to fight advanced melanoma that has stopped responding to standard treatments like anti-PD-1 (immunotherapy). If you qualify, you'd receive your own TILs instead of chemotherapy.
This trial tests a new cell therapy made from your own tumor-fighting cells (TILs) for advanced melanoma that hasn't responded to other treatments. It aims to shrink tumors by re-infusing these boosted cells back into your body.
This early-phase trial studies a combination treatment—an interferon-type medicine, an immune checkpoint antibody, and a targeted anti-angiogenesis pill—for advanced melanoma that cannot be removed with surgery. The goal is to see whether this combination can shrink tumors and be tolerated, and to learn the best way to treat this stage of melanoma.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests a modified vaccine to help the immune system recognize melanoma. It is mainly for people with melanoma at higher risk or certain stages, and who have specific inherited tissue markers on blood testing.
Hear when a new Refractory Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.